Actionable news
0
All posts from Actionable news
Actionable news in SNY: SANOFI,

France's Sanofi raises earnings forecast, pleased with eczema drug uptake

PARIS (Reuters) - France's Sanofi raised its 2017 earnings forecast, citing strong second-quarter growth in consumer healthcare, vaccines and its Genzyme unit and said it was encouraged by U.S. uptake of eczema drug Dupixent.

The drugmaker, whose shares were up 2.1 percent in early trading, said it now expected "broadly stable" earnings per share (EPS) this year compared to a previous forecast of stable to slightly lower EPS.

Sanofi's EPS in 2016 stood at 5.68 euros ($6.66).

In March, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals' and Sanofi's biologic drug for atopic dermatitis - also referred to as eczema - Dupixent, that will sell for a list price of $37,000 for a year of treatment.

While the price before discounts and rebates to insurers is far more expensive than topical medicines and steroids currently used to treat eczema, it is cheaper than other injectable...


More